MX362857B - Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos. - Google Patents

Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.

Info

Publication number
MX362857B
MX362857B MX2014004691A MX2014004691A MX362857B MX 362857 B MX362857 B MX 362857B MX 2014004691 A MX2014004691 A MX 2014004691A MX 2014004691 A MX2014004691 A MX 2014004691A MX 362857 B MX362857 B MX 362857B
Authority
MX
Mexico
Prior art keywords
hydromorphone
benzoic acid
prodrugs
methods
making
Prior art date
Application number
MX2014004691A
Other languages
English (en)
Other versions
MX2014004691A (es
Inventor
Chi Guochen
Guenther Sven
Bera Bindu
Mickle Travis
Kanski Jaroslaw
K Martin Andrea
Original Assignee
Kempharm Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc Star filed Critical Kempharm Inc Star
Publication of MX2014004691A publication Critical patent/MX2014004691A/es
Publication of MX362857B publication Critical patent/MX362857B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente invención se refiere a composiciones que comprenden ácidos aril carboxílicos químicamente conjugados a hidromorfona (4,5-a-epoxi-3-hidroxi-17-metilmorfinan-6-ona) para formar nuevos profármacos/composiciones de hidromorfona. Los profármacos de hidromorfona de la presente invención tienen efectos secundaros disminuidos y potencial disminuido para abuso comparado a hidromorfona no conjugada. La presente invención también proporciona métodos para tratar pacientes, kits farmacéuticos y métodos para sintetizar conjugados de la presente invención.
MX2014004691A 2011-10-26 2012-10-25 Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos. MX362857B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551600P 2011-10-26 2011-10-26
US201261657201P 2012-06-08 2012-06-08
PCT/US2012/061813 WO2013063204A1 (en) 2011-10-26 2012-10-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof

Publications (2)

Publication Number Publication Date
MX2014004691A MX2014004691A (es) 2014-07-09
MX362857B true MX362857B (es) 2019-02-20

Family

ID=48168468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004691A MX362857B (es) 2011-10-26 2012-10-25 Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.

Country Status (19)

Country Link
US (6) US8816083B2 (es)
EP (1) EP2771002A4 (es)
JP (1) JP5769889B2 (es)
KR (1) KR101589846B1 (es)
CN (2) CN105749294A (es)
AR (1) AR088551A1 (es)
AU (1) AU2012328837B2 (es)
BR (1) BR112014010099A8 (es)
CA (1) CA2856608C (es)
CL (1) CL2014000995A1 (es)
CO (1) CO7010825A2 (es)
HK (2) HK1197191A1 (es)
IL (1) IL231822A0 (es)
IN (1) IN2014DN03009A (es)
MX (1) MX362857B (es)
RU (1) RU2573388C2 (es)
SG (1) SG11201401856VA (es)
WO (1) WO2013063204A1 (es)
ZA (1) ZA201402339B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
IN2014DN03009A (es) * 2011-10-26 2015-05-08 Kempharm Inc
CN105934257B (zh) 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
GB201417529D0 (en) 2014-10-03 2014-11-19 Isis Innovation Beta lactamase inhibitors
WO2016086113A1 (en) 2014-11-25 2016-06-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
SG11201704309YA (en) * 2014-12-02 2017-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US9987269B2 (en) 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3231420A1 (en) * 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210596A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
US20200038383A1 (en) * 2016-10-14 2020-02-06 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
MX2020009228A (es) 2018-03-08 2021-01-08 Incyte Corp Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma.
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2021097531A1 (en) * 2019-11-22 2021-05-27 Deakin University Polyionic corrosion inhibitors
WO2021097532A1 (en) * 2019-11-22 2021-05-27 Deakin University Organic corrosion inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
RU2166512C2 (ru) * 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
DE19602962A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
KR20130010512A (ko) 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
EP1399161B1 (en) * 2001-06-05 2011-04-20 Control Delivery Systems Sustained-release analgesic compounds
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
US7375083B2 (en) 2003-09-30 2008-05-20 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004082620A2 (en) 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
US7661226B2 (en) * 2005-01-11 2010-02-16 Larson Manufacturing Company Installation method for a storm door
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
RU2469038C2 (ru) 2006-05-26 2012-12-10 Фармакофор, Инк. Контролируемое высвобождение фенольных опиатов
CA2668074A1 (en) 2006-10-31 2008-05-08 David Schwaab System for automatically shadowing data and file directory structures that are recorded on a computer memory
US20120142718A1 (en) * 2007-02-16 2012-06-07 Jenkins Thomas E N-17-Alkylated Prodrugs of Opioids
US20090186832A1 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
WO2010112942A1 (en) 2009-04-02 2010-10-07 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
CA2765836C (en) * 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
WO2011008636A1 (en) 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives
CA2768236C (en) 2009-07-16 2018-05-22 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CA2773340C (en) 2009-09-08 2019-07-23 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
CA2768199C (en) 2010-07-16 2018-08-28 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
IN2014DN03009A (es) 2011-10-26 2015-05-08 Kempharm Inc

Also Published As

Publication number Publication date
US9849185B2 (en) 2017-12-26
HK1223279A1 (zh) 2017-07-28
CA2856608A1 (en) 2013-05-02
CN105749294A (zh) 2016-07-13
US10441661B2 (en) 2019-10-15
KR101589846B1 (ko) 2016-01-28
JP2014532651A (ja) 2014-12-08
US20130150395A1 (en) 2013-06-13
RU2573388C2 (ru) 2016-01-20
US20170143839A1 (en) 2017-05-25
US10064956B2 (en) 2018-09-04
WO2013063204A1 (en) 2013-05-02
NZ623106A (en) 2015-06-26
US10258696B2 (en) 2019-04-16
HK1197191A1 (en) 2015-01-09
KR20140089520A (ko) 2014-07-15
CN104136031A (zh) 2014-11-05
ZA201402339B (en) 2015-07-29
EP2771002A1 (en) 2014-09-03
RU2014121065A (ru) 2015-12-10
CA2856608C (en) 2017-05-16
BR112014010099A8 (pt) 2018-01-16
US9566343B2 (en) 2017-02-14
BR112014010099A2 (pt) 2017-06-27
AR088551A1 (es) 2014-06-18
CO7010825A2 (es) 2014-07-31
US20190192670A1 (en) 2019-06-27
US20180339056A1 (en) 2018-11-29
AU2012328837B2 (en) 2015-07-09
MX2014004691A (es) 2014-07-09
SG11201401856VA (en) 2014-05-29
US20140330021A1 (en) 2014-11-06
US20180064820A1 (en) 2018-03-08
JP5769889B2 (ja) 2015-08-26
IL231822A0 (en) 2014-05-28
IN2014DN03009A (es) 2015-05-08
CL2014000995A1 (es) 2014-07-25
EP2771002A4 (en) 2015-08-12
AU2012328837A1 (en) 2014-05-01
US8816083B2 (en) 2014-08-26
CN104136031B (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
MX362857B (es) Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.
MY153046A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
EA201390934A1 (ru) Композиции и способы модулирования fxr
IN2014MN00988A (es)
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12017500963A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
EA201270242A1 (ru) Антипролиферативные соединения, их конъюгаты, способы их получения и их применение
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
MY162499A (en) Methylphenidate-prodrugs, processes of making and using the same
IN2015DN01119A (es)
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
PH12017500859A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
IN2013DN02555A (es)
MY162934A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
SG179153A1 (en) Pharmaceutical combination for treating tumor
UA112329C2 (uk) Композиція проліків, що містить кон'югат аспірину з гідроморфоном, та спосіб лікування захворювання
WO2009111037A3 (en) Compositions and methods for treating nos-associated diseases
WO2013101719A3 (en) Amooranin compounds and analogs thereof and related methods of use
UA111178C2 (uk) Композиція та спосіб модулювання fxr

Legal Events

Date Code Title Description
FG Grant or registration